MDL 28133A

Drug Profile

MDL 28133A

Latest Information Update: 06 Nov 1997

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aventis
  • Class Antiplatelets
  • Mechanism of Action Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Coronary thrombosis; Thrombosis

Most Recent Events

  • 06 Nov 1997 No-Development-Reported for Coronary thrombosis in USA (Unknown route)
  • 06 Nov 1997 No-Development-Reported for Thrombosis in USA (Unknown route)
  • 15 Dec 1994 A study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top